MedTrace Logo

Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)

NCT07195149 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1703

Last updated 2026-01-06

No results posted yet for this study

Summary

The purpose of this study is to compare the effect of prasugrel plus low-dose aspirin versus high dose aspirin alone (300mg) and versus low dose aspirin alone (75 mg) in patients with chronic coronary disease undergoing coronary artery bypass grafting.

Conditions

  • Chronic Coronary Syndrome
  • Stable Coronary Artery Disease CAD

Interventions

DRUG

High-Dose Aspirin 300 mg

High-dose Aspirin 300 mg once daily taken orally for three months

DRUG

DAPT (Low-Dose Aspirin 75 mg + Prasugrel 10 mg)

Drug: Prasugrel 10 mg Prasugrel 10 mg once daily taken orally for 3 months Drug: Low-Dose Aspirin 75 mg once daily taken orally

DRUG

Low-Dose Aspirin 75 mg

Low-Dose Aspirin 75 mg once daily taken orally

Sponsors & Collaborators

  • Medical Research Agency, Poland

    collaborator OTHER_GOV

  • Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.

    lead OTHER

Principal Investigators

  • Sleiman Sebastian Aboul-Hassan, MD, PhD · Zbigniew Religa Heart Center "Medinet"

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-25
Primary Completion
2030-04-30
Completion
2030-11-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07195149 on ClinicalTrials.gov